<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293069</url>
  </required_header>
  <id_info>
    <org_study_id>2016_76</org_study_id>
    <secondary_id>2017-003763-35</secondary_id>
    <nct_id>NCT03293069</nct_id>
  </id_info>
  <brief_title>Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>FAIR-ALS II</acronym>
  <official_title>Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The alteration of iron metabolism is reported in animal models of amyotrophic lateral&#xD;
      sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS. The high&#xD;
      iron concentration of the brain, due to its high energy demand (high oxygen consumption),&#xD;
      makes motor neurons particularly vulnerable to energy deficit and oxidative stress.&#xD;
      Post-mortem examinations and MRI scans in patients with ALS have found signs of iron&#xD;
      accumulation in the central motor tract; and a high level of serum ferritin, which is a&#xD;
      marker of iron levels, is associated with a lower prognosis. In ALS mouse models, the use of&#xD;
      iron chelators has demonstrated neuroprotection and increased life expectancy, suggesting&#xD;
      that elimination of excess iron from the brain can prevent neuronal loss and, consequently, a&#xD;
      slow progression of the disease. Conservative chelation of iron refers to a modality whereby&#xD;
      much of the iron that binds to the chelator is redistributed in the body rather than&#xD;
      exhausted. Using a chelator, deferiprone, with this feature, in a safety pilot study, a very&#xD;
      good safety profile was observed. Deferiprone eliminated excess iron from brain regions,&#xD;
      reduced oxidative damage and cell death associated with regional iron deposits with no&#xD;
      apparent negative impact on the iron levels needed. Now, the efficacy of this new therapeutic&#xD;
      modality of neuroprotection is being evaluated in a randomized, double-blind,&#xD;
      placebo-controlled, multicenter study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAFS score (Combined Assessment of Function and Survival)</measure>
    <time_frame>at 12 months</time_frame>
    <description>CAFS score based on changes in amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) total scores and time to death from baseline (randomization visit) to 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ALS Functional Rating Scale-Revised (ALSFRS-R) total score</measure>
    <time_frame>Baseline, at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and respiratory insufficiency mortality</measure>
    <time_frame>at 12 months</time_frame>
    <description>Time to death for all cause or respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 23 h per day for 14 consecutive days) from baseline until 12 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscle strength</measure>
    <time_frame>Baseline, at 12 months</time_frame>
    <description>Muscle strength measurements are determined by the overall mega-score for handheld dynamometry and manual muscular testing with a validated medical device provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the slow vital capacity</measure>
    <time_frame>Baseline, at 12 months</time_frame>
    <description>The slow vital capacity is measure by the maximum amount of air that can be exhaled following a deep breath. Reflecting the Respiratory insufficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Baseline, at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>Baseline, at 12 months</time_frame>
    <description>Quality of life assessed using the five-item form of the ALS assessment questionnaire (ALSAQ-5) from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSMIV criteria</measure>
    <time_frame>at 12 months</time_frame>
    <description>Dementia (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fronto-Temporal Dementia (FTD) criteria</measure>
    <time_frame>at 12 months</time_frame>
    <description>Using the revised guidelines for the diagnosis of behavioral variant frontotemporal dementia based on recent literature and collective experience by Rascovsky K et al 2011; Lamarre AK et al 2013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline, at 12 months</time_frame>
    <description>MoCA evaluated of mild cognitive dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS)</measure>
    <time_frame>Baseline, at 12 months</time_frame>
    <description>ECAS determine cognitive and behavioral changes of patients suffering from Amyotrophic Lateral Sclerosis.&#xD;
With ECAS, ALS-specific (fluency, executive functions and social cognition, language) and ALS-nonspecific (memory, visuospatial functions) functions can be analyzed to enable the distinction from other diseases with cognitive and behavioral impairments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Deferiprone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of participants will receive twice-daily oral deferiprone taken over 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day</description>
    <arm_group_label>Deferiprone</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>the placebo twice daily morning and evening.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Categorized as; possible, laboratory supported probable, probable, or definite ALS&#xD;
             (revised El Escorial criteria)&#xD;
&#xD;
          -  Spinal and bulbar forms of ALS&#xD;
&#xD;
          -  Duration of the disease of less than 18 months since the first symptoms of motor&#xD;
             deficit or amyotrophy (isolated cramps or fasciculation will not be considered).&#xD;
&#xD;
          -  Duration of the disease of less than 6 months since the diagnosis&#xD;
&#xD;
          -  An upright slow vital capacity ≥ 75% of the predicted value for age, height, and sex&#xD;
             or at least one test on inspiratory pressure ≥ 60% of the predicted value for age,&#xD;
             height, and sex which could be either maximal inspiratory pressure or a SNIFF test.&#xD;
             (The best predictive test is sniff test but sometime patients are not able to do it.)&#xD;
             (In case of a limit abnormal value for one of them, it will be recommended that&#xD;
             patient re-assessment occurs three months later).&#xD;
&#xD;
          -  A mild functional handicap score for ALSFRS-R ≥36&#xD;
&#xD;
          -  An upright slow vital capacity &gt; 70% of the predicted value for age, height, and sex&#xD;
             and&#xD;
&#xD;
          -  Able to swallow (required for oral treatment)&#xD;
&#xD;
          -  Patients weight included between 40 kg and 130 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with high frequency of comorbidity or vital risks that may reasonably impair&#xD;
             life expectancy&#xD;
&#xD;
          -  Progressing axis I psychiatric disorders (psychosis, hallucinations, substance&#xD;
             addiction, bipolar disorder, severe depression, suicidal ideation), in accordance with&#xD;
             the Diagnostic and Statistical Manual of Mental Disorders. Before entry into the&#xD;
             study, exclusion or stabilization of conditions must occur for patients suffering from&#xD;
             mild or moderate depressive episodes (not in remission) or severe and uncontrolled&#xD;
             anxiety.&#xD;
&#xD;
          -  Dementia according to the Diagnostic and Statistical Manual of Mental Disorders&#xD;
&#xD;
          -  Exposure to any other experimental drug up to 30 days before day 1&#xD;
&#xD;
          -  If the patient is under riluzole, it has to be for at least 1 month (to rule out the&#xD;
             principal risk of hepatitis; neutropenia is exceptional)&#xD;
&#xD;
          -  Due to the risk of agranulocytosis (estimated at 2%) caused by the Investigational&#xD;
             Medicinal Products (IMPs) and the unknown mechanism by which this agranulocytosis is&#xD;
             induced, combining Deferiprone with other medicinal products known to cause&#xD;
             agranulocytosis (as described in the IB) will not be allowed. Such medicinal products&#xD;
             include clozapine as well as some NSAIDs (e.g. Phenylbutazone or Metamizole),&#xD;
             antithyroid agents, sulfonamide antibiotics or methotrexate.&#xD;
&#xD;
          -  A history of relapsing neutropenia&#xD;
&#xD;
          -  Patients with agranulocytosis or with a history of agranulocytosis.&#xD;
&#xD;
          -  Hypersensitivity to Deferiprone&#xD;
&#xD;
          -  Patients with anaemia (regardless of latter aetiology) or a history of another&#xD;
             haematological disease. Haemochromatosis is not an exclusion criterion if controlled.&#xD;
&#xD;
          -  Pregnant or breastfeeding women or women of childbearing potential not taking highly&#xD;
             effective contraception.&#xD;
&#xD;
          -  Kidney or liver failure.&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  Participation in another clinical trial within 1 month prior to inclusion in the study&#xD;
&#xD;
          -  Patients under trusteeship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Devos, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Devos, MD,PhD</last_name>
    <phone>3 20.44.41.45.</phone>
    <phone_ext>+33</phone_ext>
    <email>david.devos@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chr Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chru Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pierre Wertheimer - Hcl - Bron</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Cote de Nacre - Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID DEVOS</last_name>
      <phone>+33 320446243</phone>
    </contact>
    <contact_backup>
      <last_name>PAULINE GUYON</last_name>
      <phone>+33 320446711</phone>
      <email>pauline.guyon@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>David Devos, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C H U Dupuytren Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aphm Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Nice Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hu Pitie Salpetriere Aphp</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0388116768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux - Talence</name>
      <address>
        <city>Talence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conservative Iron Chelation</keyword>
  <keyword>Disease-modifying Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

